CBS 2019
CBSMD教育中心
中 文

Acute Coronary Syndrom

Abstract

Recommended Article

OPTIMAL USE OF LIPID-LOWERING THERAPY AFTER ACUTE CORONARY SYNDROMES: A Position Paper endorsed by the International Lipid Expert Panel (ILEP) Risk Factors Associated With Major Cardiovascular Events 1 Year After Acute Myocardial Infarction Editor's Choice- Impact of immediate multivessel percutaneous coronary intervention versus culprit lesion intervention on 1-year outcome in patients with acute myocardial infarction complicated by cardiogenic shock: Results of the randomised IABP-SHOCK II trial Comparison of the Preventive Efficacy of Rosuvastatin Versus Atorvastatin in Post-Contrast Acute Kidney Injury in Patients With ST-segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention Intravenous Statin Administration During Myocardial Infarction Compared With Oral Post-Infarct Administration The prognostic role of mid-range ejection fraction in ST-segment elevation myocardial infarction New technologies for intensive prevention programs after myocardial infarction: rationale and design of the NET-IPP trial High-Sensitivity Troponin and The Application of Risk Stratification Thresholds in Patients with Suspected Acute Coronary Syndrome

Review Article2022;8:24-31 | 10.4244/AIJ-D-22-00005

JOURNAL:AsiaIntervention Article Link

Aggressive lipid-lowering therapy after percutaneous coronary intervention – for whom and how?

Z-V Lee.

Full Text PDF